In December, it was announced that the Guardian Research Network (GRN) was collaborating with life sciences company GRAIL in massive effort to revolutionize cancer detection. GRAIL’s investors include Amazon founder Jeff Bezos and Microsoft founder Bill Gates. The company is working to develop a blood test to detect cancer faster, and GRN is taking part in the research.
This collaboration, which GRN is a part of, has drawn more than $900 million in investments from pharma companies and investors, according to an article by HealthITAnalytics.
Timothy J. Yeatman, MD, president and chief scientific officer of Guardian Research Network, was quoted in that article.
“We are very pleased to be working with GRAIL and other collaborators on this landmark study and we have already begun enrolling study participants across our broad network of cancer centers and hospitals in the US,” Dr. Yeatman said.